We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported that HSBC ...

Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

Qalsody is one step closer to being covered by public Canadian healthcare systems when used to treat adults with ALS with ...

Six companies, including Alnylam Pharmaceuticals (ALNY) and Seagate Technology Holdings (STX), are set to join the Nasdaq 100 ...

If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Biogen is showing CEO Michel Vountasos to the door in the aftermath of its Aduhelm debacle. As the company searches for a new leader, one skill set stands out to investors as the most-coveted piece of ...

For years, federal prosecutors have gone after drug companies for allegedly using charity contributions as a way to boost sales. Biogen was among the pharma players to ink a federal settlement, but ...

Biogen announced it will buy Human Immunology Biosciences (HI-Bio) in a deal worth up to $1.8 billion Wednesday morning. Per terms of the transaction, Biogen will make an upfront payment of $1.15 ...